Executive Brief

News Report

The News: FDA approves Epiduo, a new OTC acne treatment gel.
Clinical Win: Improves patient access to effective acne therapy.
Target Specialty: Dermatology

Key Data at a Glance

FDA Approval Date: May 22, 2026
Active Ingredients: Adapalene and Benzoyl Peroxide
Indication: Acne Vulgaris
Dosing: Apply once daily in the evening

The FDA has approved the over-the-counter (OTC) sale of a new acne treatment gel containing adapalene and benzoyl peroxide, known as Epiduo, which is expected to enhance patient access to effective acne therapy. This approval, announced on May 22, 2026, is significant for healthcare providers as it expands treatment options for patients suffering from acne vulgaris.

Clinical Context

Acne vulgaris is a common skin condition that affects millions of individuals, particularly adolescents and young adults. It results from the interaction of multiple factors, including increased sebum production, follicular hyperkeratinization, and the presence of Propionibacterium acnes. Current treatment options range from topical agents to systemic medications, but many patients do not achieve satisfactory results with existing therapies. The combination of adapalene, a retinoid, and benzoyl peroxide, an antibacterial agent, has shown efficacy in reducing acne lesions and preventing future breakouts. The approval of Epiduo as an OTC product is expected to improve adherence and accessibility, allowing patients to manage their acne without the need for a prescription.

Key Findings

The FDA approved Epiduo, a combination of adapalene and benzoyl peroxide, for OTC use in the treatment of acne vulgaris, allowing patients to access this effective therapy without a prescription [1].

The approval is based on clinical studies demonstrating the safety and efficacy of the combination treatment in reducing acne lesions compared to placebo, with significant improvements noted in both inflammatory and non-inflammatory lesions [2].

Dosing instructions for Epiduo recommend applying a thin layer to the affected areas once daily in the evening, providing a straightforward regimen for patients [3].
Clinicians should consult current prescribing information for full dosing guidance.

The gel formulation is designed to be non-comedogenic and suitable for various skin types, enhancing its appeal to a broader patient population [4].

What This Means for Clinical Practice

The approval of Epiduo for OTC use represents a significant shift in acne management, allowing patients to take greater control over their treatment. Clinicians should be prepared to educate patients about the proper use of the gel, including the importance of consistent application and potential side effects such as dryness or irritation. This new availability may also reduce the burden on healthcare systems by decreasing the number of patients seeking prescriptions for acne treatments. However, clinicians must remain vigilant in monitoring patients who may require more intensive therapies, particularly those with moderate to severe acne or those who do not respond adequately to OTC options. The introduction of Epiduo may also prompt discussions about the role of combination therapy in acne management, emphasizing the need for personalized treatment plans that address individual patient needs and preferences.

Clinical Perspective

Workflow: Clinicians should educate patients on the proper use of Epiduo and monitor for side effects.

Economics: The OTC availability may reduce healthcare costs by decreasing prescription visits.

Patient Outcomes: Improved access to effective treatment may enhance patient satisfaction and adherence.

Dr. Divya Agarwal, Dermatology

FDA Approves Adapalene and Benzoyl Peroxide for OTC Acne Treatment: New Nonprescription Gel

Executive Brief

Key Data at a Glance

Clinical Context

Key Findings

What This Means for Clinical Practice

Clinical Perspective

References

Get weekly drug updates for Dermatology in your inbox.

Related Drug Updates

FDA Approves Over-the-Counter Adapalene and Benzoyl Peroxide for Mild to Moderate Acne Treatment

FDA Approves Icotrokinra for Moderate-to-Severe Plaque Psoriasis: Oral IL-23 Antagonist Launches New Treatment Option

FDA Approves Bimekizumab for Moderate to Severe Plaque Psoriasis: 75% Skin Clearance in BE VIVID Trial

Verified HCP Portal